Eating

Name: ADVIL PM
Brand: ADVIL PM
Price: 13.00 USD
Availability: InStock
Rating: 3.0 (2 reviews)

What are eating disorders?

Eating disorders are serious mental health disorders. They involve severe problems with your thoughts about food and your eating behaviors. You may eat much less or much more than you need.

Eating disorders are medical conditions; they are not a lifestyle choice. They affect your body's ability to get proper nutrition. This can lead to health issues, such as heart and kidney problems, or sometimes even death. But there are treatments that can help.

What are the types of eating disorders?

Common types of eating disorders include:

Binge-eating, which is out-of-control eating. People with binge-eating disorder keep eating even after they are full. They often eat until they feel very uncomfortable. Afterward, they usually have feelings of guilt, shame, and distress. Eating too much too often can lead to weight gain and obesity. Binge-eating disorder is the most common eating disorder in the U.S.
Bulimia nervosa. People with bulimia nervosa also have periods of binge-eating. But afterwards, they purge, by making themselves throw up or using laxatives. They may also over-exercise or fast. People with bulimia nervosa may be slightly underweight, normal weight, or overweight.
Anorexia nervosa. People with anorexia nervosa avoid food, severely restrict food, or eat very small quantities of only certain foods. They may see themselves as overweight, even when they are dangerously underweight. Anorexia nervosa is the least common of the three eating disorders, but it is often the most serious. It has the highest death rate of any mental disorder.

What causes eating disorders?

The exact cause of eating disorders is unknown. Researchers believe that eating disorders are caused by a complex interaction of factors. These include genetic, biological, behavioral, psychological, and social factors.

Who is at risk for eating disorders?

Anyone can develop an eating disorder, but they are more common in women. Eating disorders frequently appear during the teen years or young adulthood. But people can also develop them during childhood or later in life.

What are the symptoms of eating disorders?

The symptoms of eating disorders vary, depending on the disorder:

The symptoms of binge-eating include:

Eating unusually large amounts of food in a specific amount of time, such as a 2-hour period
Eating even when you're full or not hungry
Eating fast during binge episodes
Eating until you're uncomfortably full
Eating alone or in secret to avoid embarrassment
Feeling distressed, ashamed, or guilty about your eating
Frequently dieting, possibly without weight loss

The symptoms of bulimia nervosa include the same symptoms as binge-eating, plus trying to get rid of the food or weight after binging by:

Purging, making yourself throw up or using laxatives or enemas to speed up the movement of food through your body
Doing intensive and excessive exercise
Fasting

Over time, bulimia nervosa can cause health problems such as:

Chronically inflamed and sore throat
Swollen salivary glands in the neck and jaw area
Worn tooth enamel and increasingly sensitive and decaying teeth. This is caused by the exposure to stomach acid every time you throw up.
GERD (acid reflux) and other gastrointestinal problems
Severe dehydration from purging
Electrolyte imbalance, which could be too low or too high levels of sodium, calcium, potassium and other minerals. This can lead to a stroke or heart attack.

The symptoms of anorexia nervosa include:

Eating very little, to the point of starving yourself
Intensive and excessive exercise
Extreme thinness
Intense fear of gaining weight
Distorted body image - seeing yourself as overweight even when you are severely underweight

Over time, anorexia nervosa can cause health problems such as:

Thinning of the bones (osteopenia or osteoporosis)
Mild anemia
Muscle wasting and weakness
Thin, brittle hair and nails
Dry, blotchy, or yellowish skin
Growth of fine hair all over the body
Severe constipation
Low blood pressure
Slowed breathing and pulse
Feeling cold all the time because of a drop in internal body temperature
Feeling faint, dizzy, or weak
Feeling tired all the time
Infertility
Damage to the structure and function of the heart
Brain damage
Multiorgan failure

Anorexia nervosa can be fatal. Some people with this disorder die of complications from starvation, and others die of suicide.

Some people with eating disorders may also have other mental disorders (such as depression or anxiety) or problems with substance use.

How is eating disorders diagnosed?

Because eating disorders can be so serious, it is important to seek help if you or a loved one thinks that you might have a problem. Your health care provider may use many tools to make a diagnosis:

A medical history, which includes asking about your symptoms. It is important to be honest about your eating and exercise behaviors so your provider can help you.
A physical exam
Blood or urine tests to rule out other possible causes of your symptoms
Other tests to see whether you have any other health problems caused by the eating disorder. These can include kidney function tests and an electrocardiogram (EKG or ECG).

What are the treatments for eating disorders?

Treatment plans for eating disorders are tailored to individual needs. You will likely have a team of providers helping you, including doctors, nutritionists, nurses, and therapists. The treatments may include:

Individual, group, and/or family psychotherapy. Individual therapy may include cognitive behavioral approaches, which help you to identify and change negative and unhelpful thoughts. It also helps you build coping skills and change behavioral patterns.
Medical care and monitoring, including care for the complications that eating disorders can cause
Nutrition counseling. Doctors, nurses, and counselors will help you eat healthy to reach and maintain a healthy weight.
Medicines, such as antidepressants, antipsychotics, or mood stabilizers, may help treat some eating disorders. The medicines can also help with the depression and anxiety symptoms that often go along with eating disorders.

Some people with serious eating disorders may need to be in a hospital or in a residential treatment program. Residential treatment programs combine housing and treatment services.

NIH: National Institute of Mental Health

Eating FDA Approved Drugs

ABILIFY MAINTENA KIT [Aripiprazole^{C₂₃H₂₇Cl₂N₃O₂}]

300mg (intramuscular for suspension, extended release)

300mg/vial (intramuscular for suspension, extended release)

400mg (intramuscular for suspension, extended release)

400mg/vial (intramuscular for suspension, extended release)

Otsuka Pharm Co Ltd^{Sep 29, 2014}

Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia.
Treatment of schizophrenia.
Use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia.
Use of aripiprazole in extended release injectable suspension.

ACETADOTE [Acetylcysteine^{C₅H₉NO₃S}]

6gm/30ml (200mg/ml) (intravenous injectable)

Cumberland Pharms^{Jan 23, 2004}

Composition and method for providing a reduction in side effects for human patients in need of acetylcysteine therapy.
Method of treating acetaminophen overdose with acetylcysteine solutions.

ACULAR LS [Ketorolac Tromethamine^{C₁₅H₁₃NO₃C₄H₁₁NO₃}]

0.4% (ophthalmic solution/drops)

Allergan^{May 30, 2003}

A method of controlling postoperative ocular pain and burning/stinging in a patient.
A method of treating ocular pain and/or enhancing ocular comfort.
A method of treating ocular pain.
A method of treating or preventing ocular pain and burning.
A method of treating or preventing ocular pain and burning/stinging following corneal surgery.
A method of treating or preventing ocular pain in a patient.
A method of treating or reducing ocular pain and burning/stinging.

ADVIL PM [Diphenhydramine Hydrochloride^{C₁₇H₂₁NOClH} : Ibuprofen^{C₁₃H₁₈O₂}]

OTC

25mg : eq 200mg free acid and potassium salt (oral capsule)

Pfizer^{Dec 21, 2005}

A method of treating a patient suffering from a pain associated sleep disturbance comprising administering a liquid composition formulated inside a soft gel capsule, as claimed, to the patient.

ADVIL PM [Diphenhydramine Citrate^{C₁₇H₂₁NOC₆H₈O₇} : Ibuprofen^{C₁₃H₁₈O₂}]

OTC

38mg : 200mg (oral tablet)

Pfizer^{Dec 21, 2005}

AFREZZA [Insulin Recombinant Human]

12 units/inh (inhalation powder)

4 units/inh (inhalation powder)

8 units/inh (inhalation powder)

Mannkind^{Apr 17, 2015}

Administration of a composition comprising insulin complexed with a diketopiperazine..
Administration of a composition comprising insulin complexed with microparticles of a diketopiperazine..
Administration of fdkp microparticles comprising insulin..
Method of aerosolizing/deagglomerating an insulin dry powder for use in treating diabetes mellitus via oral inhalation using an inhaler with a cartridge containing the insulin dry powder..
Method of controlling glycemia in diabetics by administering an initial dose of insulin-fdkp with a meal; determining blood glucose level 1-2 hrs after and administering a supplemental dose of insulin-fdkp if postprandial glucose level is >140 mg/dl.
Method of delivering to a patient with diabetes mellitus in a single inhalation, greater than 75% of a dry powder dose comprising insulin and fumaryl diketopiperazine using a high resistance to flow dry powder inhaler..
Pulmonary administration of a compisition comprising insulin bound to a diketopiperazine..
Pulmonary administration of a composition comprising insulin bound to a complexing agent..
Pulmonary administration of an insulin composition comprising fdkp at the beginning of a meal to a patient also being treated with a long-acting insulin..
Treatment of a patient having diabetes mellitus with a prandial rapid acting insulin..
Treatment of diabetes mellitus with an inhaled insulin to improve glycemic control using a dry powder inhalation system comprising an inhaler, a cartridge and a dry powder medicament comprising insulin in a single inhalation.
Treatment of patient having diabetes mellitus via oral inhalation of fdkp microparticles comprising insulin.
Use of an inhaler to administer dry powder medicament.

AGGRASTAT [Tirofiban Hydrochloride^{C₂₂H₃₆N₂O₅SClHH₂O}]

eq 12.5mg base/250ml (eq 0.05mg base/ml) (injection injectable)

eq 3.75mg base/15ml (eq 0.25mg base/ml) (injection solution)

eq 5mg base/100ml (eq 0.05mg base/ml) (injection injectable)

Medicure^{Apr 20, 2000}

A dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in patients with non-st elevation acs.

ALINIA [Nitazoxanide^{C₁₂H₉N₃O₅S}]

100mg/5ml (oral for suspension)

500mg (oral tablet)

Romark^{Nov 22, 2002}

Method of treating infection by cryptosporidium parvum in an immunocompromised mammal.

ALVESCO [Ciclesonide^{C₃₂H₄₄O₇}]

0.08mg/inh (inhalation aerosol, metered)

0.16mg/inh (inhalation aerosol, metered)

Takeda Gmbh^{Jan 10, 2008}

Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a respiratory disease in a child.
Method of treating inflammatory conditions.

AMITIZA [Lubiprostone^{C₂₀H₃₂F₂O₅}]

24mcg (oral capsule)

8mcg (oral capsule)

Sucampo Pharma Llc^{Jan 31, 2006}

Method for relieving constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) 24mcg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient.
Method for relieving constipation in a patient with opioid-induced constipation that comprises administering to the patient a dosage unit comprising(i)24microg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient.
Method for relieving or treating constipation in a human constipated patient.
Method for relieving or treating constipation in a patient with irritable bowel syndrome.
Method for relieving or treating constipation in a patient with opioid-induced constipation.
Method for the long term treatment of chronic constipation in a human subject with irritable bowel syndrome.
Method for the long term treatment of chronic constipation in a human subject.
Method for treating constipation by opening cic channels in a mammalian subject.
Method for treating constipation in a patient with opioid-induced constipation by opening cic channels.
Method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome.
Method for treating opioid-induced constipation.
Method of relieving or preventing constipation in a human constipated patient.
Method of relieving or preventing constipation in a human patient with opioid-induced constipation.
Method of treating constipation in a patient with irritable bowel syndrome by opening chloride channels (cic).
Method of treating constipation in a patient with irritable bowel syndrome.
Use in relieving or preventing constipation in a human patient with a dosage unit comprising 24microg+/- 10% of a drug substance and a pharmaceutically suitable excipient.
Use in relieving or preventing constipation in a patient with opioid-induced constipation with a dosage unit comprising 24microg +/- 10% of a drug substance and a pharmaceutically suitable excipient.

ANTARA (MICRONIZED) [Fenofibrate^{C₂₀H₂₁ClO₄}]

130mg (oral capsule)

43mg (oral capsule)

90mg (oral capsule)

Lupin Atlantis^{Nov 30, 2004}

Treating hypercholesterolemias with reduction of food effect.
Treating hypertriglyceridemias with reduction of food effect.
Treating primary hypercholesterolemia and mixed dyslipidemia.
Treating severe hypertriglyceridemia.

APIDRA [Insulin Glulisine Recombinant]

1000 units/10ml (100 units/ml) (iv (infusion), subcutaneous injectable)

300 units/3ml (100 units/ml) (iv (infusion), subcutaneous injectable)

Sanofi Aventis Us^{Apr 16, 2004}

Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve.
Method of treating a patient suffering from diabetes mellitus.

APIDRA SOLOSTAR [Insulin Glulisine Recombinant]

300 units/3ml (subcutaneous injectable)

Sanofi Aventis Us^{Feb 24, 2009}

Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve.
Method of treating a patient suffering from diabetes mellitus.

APTIOM [Eslicarbazepine Acetate^{C₁₇H₁₆N₂O₃}]

200mg (oral tablet)

400mg (oral tablet)

600mg (oral tablet)

800mg (oral tablet)

Sunovion Pharms Inc^{Nov 8, 2013}

Approved indications: aptiom (eslicarbazepine acetate) is indicated as adjunctive treatment of partial-onset seizures and approved in patients with epilepsy. patent claims: in a method of treating a subject afflicted with epilepsy.
Method of treating epilepsy.
Monotherapy or adjunctive therapy for treatment of partial-onset seizures and approved in patients with epilepsy.

ARGATROBAN IN SODIUM CHLORIDE [Argatroban^{C₂₃H₃₆N₆O₅SH₂O}]

125mg/125ml (1mg/ml) (iv (infusion) injectable)

50mg/50ml (1mg/ml) (iv (infusion) injectable)

Gland Pharma Ltd^{May 22, 2017}
Sandoz^{May 9, 2011}
Eagle Pharms^{Jun 29, 2011}

AUVI-Q [Epinephrine^{C₉H₁₃NO₃}]

eq 0.15mg/delivery (intramuscular, subcutaneous injectable)

eq 0.3mg/delivery (intramuscular, subcutaneous injectable)

Kaleo Inc^{Aug 10, 2012}

Method of treating allergic reaction via injection.

AVYCAZ [Avibactam Sodium^{C₇H₁₀N₃O₆SNa} : Ceftazidime^{C₂₂H₂₁N₆O₇S₂H5H₂O}]

eq 0.5gm base : 2gm/vial (iv (infusion) powder)

Cerexa^{Feb 25, 2015}

Method of treating bacterial infections.

BELVIQ [Lorcaserin Hydrochloride]

10mg (oral tablet)

Eisai Inc^{Jun 27, 2012}

Method for chronic weight management by decreasing food intake in an individual who does not have severe renal impairment or esrd.
Method for chronic weight management by decreasing food intake.
Method for chronic weight management by inducing satiety in an individual who does not have severe renal impairment or esrd.
Method for chronic weight management by inducing satiety.
Method for chronic weight management by treating obesity in an individual who does not have severe renal impairment or esrd.
Method for chronic weight management by treating obesity.
Method for chronic weight management.
Method for chronic wieght management by controlling weight gain.
Use of belviq (lorcaserin hydrochloride) for chronic weight management by decreasing food intake in patients on a reduced-calorie diet and who have achieved greater than or equal to 5% weight loss by week 12 of treatment.
Use of belviq (lorcaserin hydrochloride) for chronic weight management by inducing satiety in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week 12 of treatment.
Use of belviq (lorcaserin hydrochloride) for chronic weight management by treating obesity in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week 12 of treatment.
Use of belviq (lorcaserin hydrochloride) for chronic weight management in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week 12 of treatment.

BELVIQ XR [Lorcaserin Hydrochloride]

20mg (oral tablet, extended release)

Eisai Inc^{Jul 15, 2016}

Method for chronic weight management by decreasing food intake in an individual who does not have severe renal impairment or esrd.
Method for chronic weight management by decreasing food intake.
Method for chronic weight management by inducing satiety in an individual who does not have severe renal impairment or esrd.
Method for chronic weight management by inducing satiety.
Method for chronic weight management by treating obesity in an individual who does not have severe renal impairment or esrd.
Method for chronic weight management by treating obesity.
Method for chronic weight management.
Method for chronic wieght management by controlling weight gain.
Use of lorcaserin hydrochloride for chronic weight management by decreasing food intake in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week 12 of treatment.
Use of lorcaserin hydrochloride for chronic weight management by inducing satiety in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week 12 of treatment.
Use of lorcaserin hydrochloride for chronic weight management by treating obesity in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week 12 of treatment.
Use of lorcaserin hydrochloride for chronic weight management in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week 12 of treatment.

BESIVANCE [Besifloxacin Hydrochloride^{C₁₉H₂₁ClFN₃O₃ClH}]

eq 0.6% base (ophthalmic suspension/drops)

Bausch And Lomb^{May 28, 2009}

Method of treating ocular bacterial infections.

BOSULIF [Bosutinib Monohydrate^{C₂₆H₂₉Cl₂N₅O₃H₂O}]

eq 100mg base (oral tablet)

eq 500mg base (oral tablet)

Pf Prism Cv^{Sep 4, 2012}

A method of treating a neoplasm.
A method of treating chronic myelogenous leukemia.

BYDUREON [Exenatide Synthetic]

2mg/vial (subcutaneous for suspension, extended release)

Astrazeneca Ab^{Jan 27, 2012}

As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Lowering plasma glucagon in a subject in need thereof, including one with type 2 diabetes, by administering an exendin or analog, such as exendin-4.
Method for treating type 2 diabetes using a sustained-release composition containing exenatide.
Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4.
Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4.
Reductions in body weight are observed with exenatide.
Treating type 2 diabetes mellitus with exenatide by stimulating insulin release.
Treatment of type 2 diabetes.

BYDUREON PEN [Exenatide Synthetic]

2mg (subcutaneous for suspension, extended release)

Astrazeneca Ab^{Feb 28, 2014}

As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Lowering plasma glucagon in a subject in need thereof, including one with type 2 diabetes, by administering an exendin or analog, such as exendin-4.
Method for treating type 2 diabetes using a sustained-release composition containing exenatide.
Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4.
Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4.
Reductions in body weight are observed with exenatide.
Treating type 2 diabetes mellitus with exenatide by stimulating insulin release.
Treatment of type 2 diabetes.

BYETTA [Exenatide Synthetic]

300mcg/1.2ml (250mcg/ml) (subcutaneous injectable)

600mcg/2.4ml (250mcg/ml) (subcutaneous injectable)

Astrazeneca Ab^{Apr 28, 2005}

Lowering plasma glucagon in a subject in need thereof, including one with type 2 diabetes, by administering an exendin or analog, such as exendin-4.
Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4.
Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4.
Stimulating insulin release by administering exenatide.
Treating type 2 diabetes mellitus with exenatide by stimulating insulin release.
Use of exenatide may result in reduction in appetite..
Use of exenatide may result in reduction in body weight.

BYVALSON [Nebivolol Hydrochloride^{C₂₂H₂₅F₂NO₄ClH} : Valsartan^{C₂₄H₂₉N₅O₃}]

eq 5mg base : 80mg (oral tablet)

Forest Labs Llc^{Jun 3, 2016}

Method of treating hypertension.

CALDOLOR [Ibuprofen^{C₁₃H₁₈O₂}]

800mg/8ml (100mg/ml) (intravenous solution)

Cumberland Pharms^{Jun 11, 2009}

Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics in a critically ill patient with intravenous ibuprofen in need thereof.
Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity.
Management of mild to moderate pain, management of moderate to severe pain as an adnunct to opioid analgesics, reduction in fever through anti inflammatory, analgesic, and antipyretic activity.
Methods of treating pain, inflammation and/or fever in a critically ill patient with intravenous ibuprofen in need thereof.
Methods of treating pain, inflammation and/or fever with intravenous ibuprofen such that mean arterial blood pressure does not increase the dosage interval.

CARDENE [Nicardipine Hydrochloride^{C₂₆H₂₉N₃O₆ClH}]

25mg/10ml (2.5mg/ml) (injection injectable)

Chiesi Usa Inc^{Jan 30, 1992}

Method for treating acute elevations of blood pressure in human subject in need thereof.

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER [Nicardipine Hydrochloride^{C₂₆H₂₉N₃O₆ClH}]

40mg/200ml (0.2mg/ml) (intravenous injectable)

Chiesi Usa Inc^{Nov 7, 2008}

Method for treating acute elevations of blood pressure in human subject in need thereof.

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER [Nicardipine Hydrochloride^{C₂₆H₂₉N₃O₆ClH}]

20mg/200ml (0.1mg/ml) (intravenous injectable)

Chiesi Usa Inc^{Jul 31, 2008}

Method for treating acute elevations of blood pressure in human subject in need thereof.

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER [Nicardipine Hydrochloride^{C₂₆H₂₉N₃O₆ClH}]

20mg/200ml (0.1mg/ml) (intravenous injectable)

Chiesi Usa Inc^{Jul 31, 2008}

Method for treating acute elevations of blood pressure in human subject in need thereof.

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER [Nicardipine Hydrochloride^{C₂₆H₂₉N₃O₆ClH}]

40mg/200ml (0.2mg/ml) (intravenous injectable)

Chiesi Usa Inc^{Nov 7, 2008}

Method for treating acute elevations of blood pressure in human subject in need thereof.

CETYLEV [Acetylcysteine^{C₅H₉NO₃S}]

2.5gm (oral tablet, effervescent)

500mg (oral tablet, effervescent)

Arbor Pharms Llc^{Jan 29, 2016}

Method of treating acetaminophen overdose with acetylcysteine solutions.

CLARINEX [Desloratadine^{C₁₉H₁₉ClN₂}]

0.5mg/ml (oral solution)

2.5mg (oral tablet, orally disintegrating)

Merck Sharp Dohme^{Sep 1, 2004}

CLARINEX D 24 HOUR [Desloratadine^{C₁₉H₁₉ClN₂} : Pseudoephedrine Sulfate^{2C₁₀H₁₅NOH₂O₄S}]

5mg : 240mg (oral tablet, extended release)

Merck Sharp Dohme^{Mar 3, 2005}

A method of treating nasal and non-nasal symptoms of seasonal allergic rhinitis.

CLARINEX-D 12 HOUR [Desloratadine^{C₁₉H₁₉ClN₂} : Pseudoephedrine Sulfate^{2C₁₀H₁₅NOH₂O₄S}]

2.5mg : 120mg (oral tablet, extended release)

Merck Sharp Dohme^{Feb 1, 2006}

A method of treating nasal and non-nasal symptoms of seasonal allergic rhinitis.
Allergic rhinitis.

CLINDESSE [Clindamycin Phosphate^{C₁₈H₃₄ClN₂O₈PS}]

eq 2% base (vaginal cream)

Perrigo Pharma Intl^{Nov 30, 2004}

Method of treating bacterial vaginosis.

COLCRYS [Colchicine^{C₂₂H₂₅NO₆}]

0.6mg (oral tablet)

Takeda Pharms Usa^{Jul 29, 2009}

A method for treatment of gout flares during prophylaxis.
For the treatment and prophylaxis of gout flares & the treatment of familial mediterranean fever.
Method of administering colchicine to familial mediterranean fever patients.
Method of treating gout flares.
Method of using colchicine for the prophylaxis of gout flares.

COMETRIQ [Cabozantinib S-malate^{C₂₈H₂₄FN₃O₅C₄H₆O₅}]

eq 20mg base (oral capsule)

eq 80mg base (oral capsule)

Exelixis^{Nov 29, 2012}

Method of treating medullary thyroid cancer.

CONCERTA [Methylphenidate Hydrochloride^{C₁₄H₁₉NO₂ClH}]

18mg (oral tablet, extended release)

27mg (oral tablet, extended release)

36mg (oral tablet, extended release)

54mg (oral tablet, extended release)

Janssen Pharms^{Aug 1, 2000}

For claims 1-3,6-13,16-24 and 26-32: method of treating adhd.
For claims 1-4,6-14,16-24 and 26-32: method of treating adhd in children 6 years of age and older and adolescents.
Method of treating adhd in children 6 years of age and older and adolescents.
Method of treating adhd.

CONTRAVE [Bupropion Hydrochloride^{C₁₃H₁₈ClNOClH} : Naltrexone Hydrochloride^{C₂₀H₂₃NO₄ClH}]

90mg : 8mg (oral tablet, extended release)

Orexigen^{Sep 10, 2014}

For chronic weight management for treating overweight or obesity.
For effect on blood glucose parameters in patients with insulin resistance.
Use of naltrexone and bupropion based on an escalating dose schedule.
Use of naltrexone and bupropion for chronic weight management for treating overweight or obesity in patients with major depressive disorder.
Use of naltrexone and bupropion in a layered formulation for chronic weight management for affecting weight loss.
Use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity.

COPAXONE [Glatiramer Acetate^{(C₉H₉NO₂)n(C₆H₁₂N₂O)n(C₅H₇NO₃)n(C₃H₅NO)nC₂H₄O₂}]

20mg/ml (subcutaneous injectable)

40mg/ml (subcutaneous injectable)

Teva Pharms Usa^{Feb 12, 2002}

Method of treating ms by administering copaxone.

CORLANOR [Ivabradine Hydrochloride^{C₂₇H₃₆N₂O₅ClH}]

eq 5mg base (oral tablet)

eq 7.5mg base (oral tablet)

Amgen Inc^{Apr 15, 2015}

A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride.

CRIXIVAN [Indinavir Sulfate^{C₃₆H₄₇N₅O₄H₂O₄S}]

eq 200mg base (oral capsule)

eq 400mg base (oral capsule)

Merck Sharp Dohme^{Mar 13, 1996}

Treating hiv infection with indinavir sulfate in combination with antiretroviral agents.

DORAL [Quazepam^{C₁₇H₁₁ClF₄N₂S}]

15mg (oral tablet)

Cutis Health Llc^{Dec 27, 1985}

Method for treating insomnia while reducing the risk of an adverse drug interaction.

EDLUAR [Zolpidem Tartrate^{2C₁₉H₂₁N₃OC₄H₆O₆}]

10mg (sublingual tablet)

5mg (sublingual tablet)

Mylan Speciality Lp^{Mar 13, 2009}

Method of treating insomnia characterized by difficulty with sleep onset.

ELELYSO [Taliglucerase Alfa]

200 units/vial (iv (infusion) powder)

Pfizer^{May 1, 2012}

A method of catalyzing the hydrolysis of glucocerebroside to glucose and ceramide..
A method of treating gaucher's disease.

ELIGARD [Leuprolide Acetate^{C₅₉H₈₄N₁₆O₁₂C₂H₄O₂}]

22.5mg/vial (subcutaneous injectable)

30mg/vial (subcutaneous injectable)

45mg/vial (subcutaneous injectable)

7.5mg/vial (subcutaneous injectable)

Tolmar Therap^{Jul 24, 2002}

Method of treating cancer.

ENABLEX [Darifenacin Hydrobromide^{C₂₈H₃₀N₂O₂BrH}]

eq 15mg base (oral tablet, extended release)

eq 7.5mg base (oral tablet, extended release)

Apil^{Dec 22, 2004}

Treating urinary incontinence by administering an extended-release form of darifenacin.

ENTEREG [Alvimopan^{C₂₅H₃₂N₂O₄2H₂O}]

12mg (oral capsule)

Cubist Pharms^{May 20, 2008}

A method of treating or preventing ileus.
A method to accelerate the time to gastrointestinal recovery by administering about 12 mg of alvimopan to the patient from about 30 to 60 minutes prior to surgery.
Accelerating the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection with primary anastomosis.
Treating a subject undergoing abdominal surgery by administering alvimopan to accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection with primary anastomosis.

EPANED KIT [Enalapril Maleate^{C₂₀H₂₈N₂O₅C₄H₄O₄}]

1mg/ml (oral for solution)

Silvergate Pharms^{Aug 13, 2013}

Method of treating hypertension.
Method of treating left ventricular dysfunction.
Method of treatment of heart failure.
Treatment of heart failure.
Treatment of hypertension.

EUCRISA [Crisaborole^{C₁₄H₁₀BNO₃}]

2% (topical ointment)

Anacor Pharms Inc^{Dec 14, 2016}

Method of treating mild to moderate atopic dermatitis..

EVOTAZ [Atazanavir Sulfate^{C₃₈H₅₂N₆O₇H₂O₄S} : Cobicistat^{C₄₀H₅₃N₇O₅S₂}]

eq 300mg base : 150mg (oral tablet)

Bristol-myers Squibb^{Jan 29, 2015}

Method for treating hiv-1 infection.
Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase.

EXCEDRIN (MIGRAINE) [Acetaminophen^{C₈H₉NO₂} : Aspirin^C₉H₈O₄ : Caffeine^{C₈H₁₀N₄O₂}]

OTC

250mg : 250mg : 65mg (oral tablet)

Glaxosmithkline Cons^{Jan 14, 1998}

Treating migraine pain and one or more of a cluster of symptoms characteristic of a migraine attack symptoms being selected from photophobia, phonophobia nausea and functional disability.

EXJADE [Deferasirox^{C₂₁H₁₅N₃O₄}]

125mg (oral tablet, for suspension)

250mg (oral tablet, for suspension)

500mg (oral tablet, for suspension)

Novartis^{Nov 2, 2005}

Method of treating chronic iron overload.

FANAPT [Iloperidone^{C₂₄H₂₇FN₂O₄}]

10mg (oral tablet)

12mg (oral tablet)

1mg (oral tablet)

4mg (oral tablet)

6mg (oral tablet)

8mg (oral tablet)

Vanda Pharms Inc^{May 6, 2009}

Dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone.
Dosage modification to reduce the risk associated with qt prolongation not induced by other drugs during treatment with iloperidone.
Indicated for the acute treatment of adults with schizophrenia.
Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are being treated with fluoxetine.
Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are poor metabolizers of cyp2d6.

FENOGLIDE [Fenofibrate^{C₂₀H₂₁ClO₄}]

120mg (oral tablet)

40mg (oral tablet)

Santarus Inc^{Aug 10, 2007}

For reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides, and treating hypertriglyceridemia.
Use of fenofibrate for reducing elevated total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides.

FERAHEME [Ferumoxytol]

eq 510mg iron/17ml (eq 30mg iron/ml) (intravenous solution)

Amag Pharms Inc^{Jun 30, 2009}

Method of treating patients needing an iron supplement.

FERRIPROX [Deferiprone^{C₇H₉NO₂}]

100mg/ml (oral solution)

500mg (oral tablet)

Apopharma Inc^{Sep 9, 2015}

Method of treating chronic iron overload.

FIRMAGON [Degarelix Acetate^{C₈₂H₁₀₃ClN₁₈O₁₆C₂H₄O₂H₂O}]

eq 120mg base/vial (subcutaneous powder)

eq 80mg base/vial (subcutaneous powder)

Ferring^{Dec 24, 2008}

Gnrh antagonist indicated for treatment of patients with advanced prostate cancer.
Method of treating prostate cancer.
Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect.

FLOVENT HFA [Fluticasone Propionate^{C₂₅H₃₁F₃O₅S}]

0.044mg/inh (inhalation aerosol, metered)

0.11mg/inh (inhalation aerosol, metered)

0.22mg/inh (inhalation aerosol, metered)

Glaxo Grp Ltd^{May 14, 2004}

Method of treating a condition capable of treatment by inhalation, e.g. asthma, comprising administration of a formulation claimed in us patent no. 6743413.

FOCALIN XR [Dexmethylphenidate Hydrochloride^{C₁₄H₁₉NO₂ClH}]

10mg (oral capsule, extended release)

15mg (oral capsule, extended release)

20mg (oral capsule, extended release)

25mg (oral capsule, extended release)

30mg (oral capsule, extended release)

35mg (oral capsule, extended release)

40mg (oral capsule, extended release)

Novartis^{May 26, 2005}

Method of treating attention deficit disorder using oral administration of a bi-modal or pulsatile release composition.

FOLLISTIM AQ [Follitropin Alfa/beta]

300 iu/0.36ml (subcutaneous injectable)

600 iu/0.72ml (subcutaneous injectable)

900 iu/1.08ml (subcutaneous injectable)

Organon Usa Inc^{Mar 23, 2004}

A method for administering follicle stimulating hormone (fsh) for ovarian follicle or testicular stimulation in the human.
Method of administering fsh for the treatment of infertility through induction of ovulation and pregnancy in anovulatory infertile women.
Method of treating infertility.
Treatment of infertility through induction of ovulation and pregnancy to anovulatory infertile women.

FORTEO [Teriparatide Recombinant Human]

0.6mg/2.4ml (0.25mg/ml) (subcutaneous injectable)

Lilly^{Jun 25, 2008}

A method of treating osteoporosis.
Forteo is indicated for the treatment of post menopausal women with osteoporosis who are at high risk for fracture.
Forteo is indicated for the treatment of post menopausal women with osteoporosis who are at risk for fracture. forteo can be used by people who have had a fracture related to osteoporosis.
Method for the treatment of a woman with osteoporosis and at risk for bone fracture.
Method of treating osteoporosis in a post-menopausal woman at risk for fracture.
Method of treatment of osteoporosis wherein the osteoporosis is steroid-induced.
Treatment of a woman with osteoporosis and a high risk for bone fracture by reducing the risk of vertebral and nonvertebral bone fracture.

GLEEVEC [Imatinib Mesylate^{C₂₉H₃₁N₇OCH₄O₃S}]

eq 100mg base (oral tablet)

eq 400mg base (oral tablet)

Novartis^{Apr 18, 2003}

A method for treating a tumor disease.
Gleevec is also indicated for the treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (gist).
Treatment of gastrointestinal stromal tumors (gist).

GLUCOPHAGE XR [Metformin Hydrochloride^{C₄H₁₁N₅ClH}]

500mg (oral tablet, extended release)

750mg (oral tablet, extended release)

Bristol Myers Squibb^{Oct 13, 2000}

Method of treating patient with type 2 diabetes by once daily administration.

GLUCOTROL XL [Glipizide^{C₂₁H₂₇N₅O₄S}]

10mg (oral tablet, extended release)

2.5mg (oral tablet, extended release)

Pfizer^{Apr 26, 1994}

Method of treating hyperglycemia to improve glycemic control in a patient by oral admin of once a day osmotic dosage form of glipizide with polyethylene oxide, hydroxypropylmethylcellulose, cellulose acetate, and sodium chloride.

GLYXAMBI [Empagliflozin^{C₂₃H₂₇ClO₇} : Linagliptin^{C₂₅H₂₈N₈O₂}]

10mg : 5mg (oral tablet)

25mg : 5mg (oral tablet)

Boehringer Ingelheim^{Jan 30, 2015}

Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without insulin or a sulfonylurea).
Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without metformin).
Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin.
Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin.

IBRANCE [Palbociclib^{C₂₄H₂₉N₇O₂}]

100mg (oral capsule)

125mg (oral capsule)

75mg (oral capsule)

Pfizer Inc^{Feb 3, 2015}

Treating hr-pos., her2-neg. advanced or metastatic breast cancer with palbociclib in combo with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women or fulvestrant in women with disease progression after endocrine therapy.

ICLUSIG [Ponatinib Hydrochloride^{C₂₉H₂₇F₃N₆OClH}]

eq 15mg base (oral tablet)

eq 30mg base (oral tablet)

eq 45mg base (oral tablet)

Ariad^{Dec 14, 2012}

A method for the treatment of leukemias.
A method for treating acute lymphoblastic leukemia.
A method for treating chronic myeloid leukemia.
A method for treating leukemia resulting from a mutation in the bcr-abl kinase domain.
A method for treating philadelphia chromosome positive acute lymphoblastic leukemia.
A method of treating chronic myelogenous leukemia.

INOMAX [Nitric Oxide^NO]

800ppm (inhalation gas)

Mallinckrodt Hosp^{Dec 23, 1999}

A method of providing a predetermined concentration of nitric oxide to a patient.
A method of providing nitric oxide therapy to a patient by compensating long-term sensitivity drift of electrochemical gas sensors used in systems for delivering therapeutic nitric oxide to a patient.
A method of providing nitric oxide therapy to a patient by verifying gas information of nitric oxide prior to delivery to patient.
A method of providing nitric oxide therapy to a patient.
A method of purging a nitric oxide delivery system.
A method of reducing the risk of pulmonary edema in patients in need of treatment with inhaled nitric oxide.
A method of treating hypoxic respiratory failure by verifying gas information of nitric oxide prior to delivery to patient.

INSPRA [Eplerenone^{C₂₄H₃₀O₆}]

25mg (oral tablet)

50mg (oral tablet)

Gd Searle Llc^{Sep 27, 2002}

Treatment of conditions for which an aldosterone receptor blocker is indicated, such as hypertension, heart failure, and post-myocardial infarction.
Treatment of conditions related to hyperaldosteronism such as hypertension and cardiac insufficiency, with eplerenone.
Treatment of hypertension.
Use of eplerenone in combination with an angiotensin converting enzyme (ace) inhibitor (and optionally a diuretic) for treating congestive heart failure and hypertension.
Use of eplerenone in combination with an angiotensin converting enzyme (ace) inhibitor for treating hypertension.

INTERMEZZO [Zolpidem Tartrate^{2C₁₉H₂₁N₃OC₄H₆O₆}]

1.75mg (sublingual tablet)

3.5mg (sublingual tablet)

Purdue Pharma^{Nov 23, 2011}

Method for treating insomnia.
Method of treating middle-of-the-night insomnia.

IXEMPRA KIT [Ixabepilone^{C₂₇H₄₂N₂O₅S}]

15mg/vial (iv (infusion) injectable)

45mg/vial (iv (infusion) injectable)

R-pharm Us Llc^{Oct 16, 2007}

A method of treating cancer in a patient comprising administering ixabepilone or pharmaceutical compositions comprising ixabepilone.
Method of treating breast cancer by administering ixabepilone; a method of treating a cancer responsible to microtubule stabilization by administering ixabepilone.
Method of treating cancer in a patient comprising intravenously administering to the patient ixabepilone diluted in a parenteral diluent.
Method of treating cancer, iv admin, lyophylized ixabepilone diluted, every week or 3 weeks; lyophilized ixabepilone with solvent(dehydrated ethanol) diluted to concentration of 0.1mg/ml to 0.9mg/ml.
Method of treating patient comprising mixing first and second vials of product comprising lyophilized ixabepilone to provide an epothilone analog solution, diluting solution with a suitable diluent to prepare intravenous formulation for pt.
Use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer.

JADENU [Deferasirox^{C₂₁H₁₅N₃O₄}]

180mg (oral tablet)

360mg (oral tablet)

90mg (oral tablet)

Novartis Pharms Corp^{Mar 30, 2015}

Method of treating chronic iron overload.

JANUMET [Metformin Hydrochloride^{C₄H₁₁N₅ClH} : Sitagliptin Phosphate^{C₁₆H₁₅F₆N₅OH₂OH₃O₄P}]

1gm : eq 50mg base (oral tablet)

500mg : eq 50mg base (oral tablet)

Merck Sharp Dohme^{Mar 30, 2007}

Improvement of glycemic control in adults with type 2 diabetes mellitus.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with metformin and a ppar-gamma agonist.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor.

JANUMET XR [Metformin Hydrochloride^{C₄H₁₁N₅ClH} : Sitagliptin Phosphate^{C₁₆H₁₅F₆N₅OH₂OH₃O₄P}]

1gm : eq 100mg base (oral tablet, extended release)

1gm : eq 50mg base (oral tablet, extended release)

500mg : eq 50mg base (oral tablet, extended release)

Merck Sharp Dohme^{Feb 2, 2012}

Improvement of glycemic control in adults with type 2 diabetes mellitus.
Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended release is appropriate.

JANUVIA [Sitagliptin Phosphate^{C₁₆H₁₅F₆N₅OH₂OH₃O₄P}]

eq 100mg base (oral tablet)

eq 25mg base (oral tablet)

eq 50mg base (oral tablet)

Merck Sharp Dohme^{Oct 16, 2006}

Improvement of glycemic control in adults with type 2 diabetes mellitus in combination with metformin and/or a ppar-gamma agonist and/or sulfonylurea and/or insulin.
Improvement of glycemic control in adults with type 2 diabetes mellitus in combination with metformin..
Improvement of glycemic control in adults with type 2 diabetes mellitus.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with metformin and a ppar-gamma agonist.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with a ppar-gamma agonist.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidaste-iv inhibitor.

JARDIANCE [Empagliflozin^{C₂₃H₂₇ClO₇}]

10mg (oral tablet)

25mg (oral tablet)

Boehringer Ingelheim^{Aug 1, 2014}

Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin.

JENTADUETO [Linagliptin^{C₂₅H₂₈N₈O₂} : Metformin Hydrochloride^{C₄H₁₁N₅ClH}]

2.5mg : 1gm (oral tablet)

2.5mg : 500mg (oral tablet)

2.5mg : 850mg (oral tablet)

Boehringer Ingelheim^{Jan 30, 2012}

Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with metformin.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor.
Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin.

JENTADUETO XR [Linagliptin^{C₂₅H₂₈N₈O₂} : Metformin Hydrochloride^{C₄H₁₁N₅ClH}]

2.5mg : 1gm (oral tablet, extended release)

Boehringer Ingelheim^{May 27, 2016}

Method of treating type 2 diabetes in patients who have not been previously treated with an antihyperglycemic agent by administering linagliptin in combination with metformin.
Method of treating type 2 diabetes in patients with insufficient glycemic control despite therapy with one or more conventional antihyperglycemic agents by administering linagliptin in combination with metformin.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and, optionally, a sulfonylurea.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor.
Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin.
Method of treating type 2 diabetes.

KALYDECO [Ivacaftor^{C₂₄H₂₈N₂O₃}]

150mg (oral tablet)

50mg/packet (oral granule)

75mg/packet (oral granule)

Vertex Pharms^{Jan 31, 2012}
Vertex Pharms Inc^{Mar 17, 2015}

Method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide.
Method of treating a patient having cystic fibrosis, the patient having a r117h mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide.
Method of treating cystic fibrosis.

KAZANO [Alogliptin Benzoate^{C₁₈H₂₁N₅O₂C₇H₆O₂} : Metformin Hydrochloride^{C₄H₁₁N₅ClH}]

eq 12.5mg base : 1gm (oral tablet)

eq 12.5mg base : 500mg (oral tablet)

Takeda Pharms Usa^{Jan 25, 2013}

Method of treating diabetes comprising administering a compound such as alogliptin.
Method of treating diabetes comprising administering alogliptin.
Methods of lowering elevated post prandial blood glucose levels comprising administering a dipeptidyl peptidase inhibitor.
Methods of modifying glucose metabolism and treating diabetes comprising administering a dipeptidyl peptidase inhibitor and one or more other therapeutic agents such as metformin.
Methods of reducing the side effects of active components administered to a diabetic patient comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer.
Methods of treating diabetes comprising administering a dipeptidyl peptidase inhibitor and metformin.

KENGREAL [Cangrelor^{C₁₇H₂₅Cl₂F₃N₅O₁₂P₃S₂}]

50mg/vial (iv (infusion) powder)

Chiesi Usa Inc^{Jun 22, 2015}

Method of treating, reducing the incidence of, or preventing an ischemic event in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and continuous infusion of 4 ug/kg/min for at least 2 hours or the duration of the pci.
P2y12 platelet inhibitor for use as adjunct to percutaneous coronary intervention to reduce risk of various diseases/conditions in patients not treated with a p2y12 platelet inhibitor and not given a glycoprotein iib/iiia inhibitor.

KOMBIGLYZE XR [Metformin Hydrochloride^{C₄H₁₁N₅ClH} : Saxagliptin Hydrochloride^{C₁₈H₂₅N₃O₂ClH}]

1gm : eq 2.5mg base (oral tablet, extended release)

1gm : eq 5mg base (oral tablet, extended release)

500mg : eq 5mg base (oral tablet, extended release)

Astrazeneca Ab^{Nov 5, 2010}

Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.
Method for treating type ii diabetes mellitus by administering saxagliptin in combination with metformin.

KORLYM [Mifepristone^{C₂₉H₃₅NO₂}]

300mg (oral tablet)

Corcept Therap^{Feb 17, 2012}

Treating cushing's syndrome.

LENVIMA [Lenvatinib Mesylate^{C₂₁H₁₉ClN₄O₄CH₄O₃S}]

eq 10mg base (oral capsule)

eq 4mg base (oral capsule)

Eisai Inc^{Feb 13, 2015}

Method for treating thyroid carcinoma including differentiated thyroid cancer.

LINZESS [Linaclotide^{C₅₉H₇₉N₁₅O₂₁S₆}]

145mcg (oral capsule)

290mcg (oral capsule)

72mcg (oral capsule)

Forest Labs Llc^{Aug 30, 2012}

Method of treating chronic idiopathic constipation in adult patients..
Method of treating irritable bowel syndrome with constipation in adult patients..
Method of treating irritable bowel syndrome with constipation in adults.

LOTREL [Amlodipine Besylate^{C₂₀H₂₅ClN₂O₅C₆H₆O₃S} : Benazepril Hydrochloride^{C₂₄H₂₈N₂O₅ClH}]

eq 10mg base : 20mg (oral capsule)

eq 10mg base : 40mg (oral capsule)

eq 2.5mg base : 10mg (oral capsule)

eq 5mg base : 10mg (oral capsule)

eq 5mg base : 20mg (oral capsule)

eq 5mg base : 40mg (oral capsule)

Novartis^{Jun 20, 2002}

Method of treating hypertension.
Treatment of cardiovascular disorders.

LUMIGAN [Bimatoprost^{C₂₅H₃₇NO₄}]

0.01% (ophthalmic solution/drops)

Allergan^{Aug 31, 2010}

A method of lowering intraocular pressure in a patient with open angle glaucoma or ocular hypertension.
A method of lowering intraocular pressure.
A method of reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension.
A method of treating a patient with glaucoma or ocular hypertension.
Method of treating glaucoma in a patient.
Method of treating glaucoma or elevated intraocular pressure.
Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension.

MINOCIN [Minocycline Hydrochloride^{C₂₃H₂₇N₃O₇ClH}]

eq 100mg base (oral capsule)

eq 100mg base/vial (injection injectable)

eq 50mg base (oral capsule)

Precision Dermat^{May 31, 1990}
Rempex Pharms Inc^{Approved Prior To Jan 1, 1982}

MOXATAG [Amoxicillin^{C₁₆H₁₉N₃O₅S3H₂O}]

775mg (oral tablet, extended release)

Vernalis R And D Ltd^{Jan 23, 2008}

Method of treating tonsillitis and/or pharyngitis secondary to streptococcus pyogenes in a once-a-day amoxicillin product.
Use of once-a-day amoxicillin product to treat tonsillitis and/or pharyngitis secondary to streptococcus pyogenes.

NESINA [Alogliptin Benzoate^{C₁₈H₂₁N₅O₂C₇H₆O₂}]

eq 12.5mg base (oral tablet)

eq 25mg base (oral tablet)

eq 6.25mg base (oral tablet)

Takeda Pharms Usa^{Jan 25, 2013}

Method of treating diabetes comprising administering a compound such as alogliptin.
Method of treating diabetes comprising administering alogliptin.
Methods of lowering elevated post prandial blood glucose levels comprising administering a dipeptidyl peptidase inhibitor.
Methods of modifying glucose metabolism and treating diabetes comprising administering a dipeptidyl peptidase inhibitor and one or more other therapeutic agents such as metformin.
Methods of reducing the side effects of active components administered to a diabetic patient comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer.
Methods of treating diabetes comprising administering a dipeptidyl peptidase inhibitor and metformin.

NEVANAC [Nepafenac^{C₁₅H₁₄N₂O₂}]

0.1% (ophthalmic suspension/drops)

Novartis Pharms Corp^{Aug 19, 2005}

Method of treating ocular inflammation.

NEXIUM 24HR [Esomeprazole Magnesium^{2C₁₇H₁₈N₃O₃SMg3H₂O}]

OTC

eq 20mg base (oral capsule, delayed release)

Astrazeneca Lp^{Mar 28, 2014}

Treatment of frequent heartburn by administering a gastric acid reducer.
Treatment of frequent heartburn by administering omeprazole according to claims 1-8.
Treatment of frequent heartburn by administering s-omeprazole trihydrate according to claims 1-3.

NIASPAN [Niacin^{C₆H₅NO₂}]

1gm (oral tablet, extended release)

500mg (oral tablet, extended release)

750mg (oral tablet, extended release)

Abbvie^{Jul 28, 1997}

A method of reducing the capacity of extended release nicotinic acid to provoke a flushing reaction by pretreating an individual with a flush inhibiting agent prior to the administration of the extended release nicotinic acid.
Method of treating hyperlipidemia with nicotinic acid by dosing once per day in the evening or at night.
Reduction in elevated tc and ldl-c by dosing once per day in the evening or at night, with pretreatment with a flush inhibitin agent such as aspirin.
Reduction in elevated tc and ldl-c by dosing once per day in the evening or at night.
Reduction in risk of recurrent nonfatal myocardial infarction by dosing once per day in the evening or a t night, with pretreatment with a flush inhibitin agent such as aspirin.
Reduction in risk of recurrent nonfatal myocardial infarction by dosing once per day in the evening or at night.
Reduction in tg by dosing once per day in the evening or at night, with pretreatment with a flush inhibiting agent such as aspirin.
Reduction in tg by dosing once per day in the evening or at night.
Treatment of primary and mixed dyslipidemia by dosing once per day in the evening or at night, with pretreatment with a flush inhibiting agent such as aspirin.
Treatment of primary and mixed dyslipidemia by dosing once per day in the evening or at night.

NINLARO [Ixazomib Citrate^{C₂₀H₂₃BCl₂N₂O₉}]

eq 2.3mg base (oral capsule)

eq 3mg base (oral capsule)

Millennium Pharms^{Nov 20, 2015}

Method for treating cancer, including multiple myeloma.
Method for treating multiple myeloma with one or more other therapeutic agents.
Method for treating multiple myeloma.

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.

WARNING: All medicines, drugs, plants, chemicals or medicial precedures below are for reference only. Many of these treatments may be harmful and possibly fatal. Do not consume any plant, chemical, drug or otherwise without first consulting a licensed physician that practices medine in the appropriate field. The owner of this website will not be held liable for any injuries and deaths cause by following any home remedies. We have no control of what is posted.

Home Remedies for Eating

ERECTILE DYSFUNCTION - ED [impotence]
The most popular pharmaceutical remedy for ED are Cialis (tadalafil) or Viagra (sildenafil). Both are phosphodiesterase-5 (PDE5) inhibitors for treating impotence. Other drugs to treat erectile dysfunction (ED) include Stendra, Staxyn and Levitra.

Erectile dysfunction can be a symptom of a serious health problem. Consult a physician if you are experiencing impotence over a long period.
Mechanism - phosphodiesterase-5 PDE5 inhibitorsMaryFreeman | May 15th, 2020

SORE THROAT [Pharyngitis]
...a, lethargy, and/or congestive heart failure. The NIH has determined that there is insufficient data available to know if licorice is effective in treating any medical condition.

The FDA notes:
-Don’t eat large amounts of black licorice at one time.
-If you have been eating a lot of black ...... amounts of black licorice at one time.
-If you have been eating a lot of black licorice and have an irregular heart rhythm or muscle weakness, stop eating it immediately and contact your healthcare provider.
-Black licorice can interact with some medications, herbs and dietary supplements. Consul...
Mechanism - glycyrrhizinJlaiii | August 11th, 2020

Reference:

Bergner, Pal., Griswold, Alexandra F., Hufford, David J., et al. . Morton Grove, Il: Publications International, 2017.¹

WARNING: All medicines, drugs, plants, chemicals or medicial precedures below are for historical reference only. Many of these treatments are now known to be harmful and possibly fatal. Do not consume any plant, chemical, drug or otherwise without first consulting a licensed physician that practices medine in the appropriate field.

Felter's Materia Medica on Eating

ACONITUM NEPALLUS
The dried tuberous root of Aconitum Napellus, Linné... / ...nd a general glow of the surface follow non-lethal doses. Slight perspiration may be induced, but sweating to any great degree does not take place except from large doses. Then it is an almost constan......body, the thrilling and creeping coldness approaching from the extremities to the body. Excessive sweating comes on, rapidly lowering the body temperature, dimness of vision, ²

ÆSCULUS GLABRA
The bark and fruit of Aesculus glabra, Willdenow (Nat. Ord. Sapindaceae). A small fetid tree common to the central portion of the United... / ... doses these symptoms are increased, coma comes on, and the victim dies. Cattle are often killed by eating buckeyes; if not fatal, a condition known as "blind staggers" is produced. Therapy.Aesculus... / ...Aesculus deserves further study to determine its status as a remedy for nervous disorders, and especially its control over visceral neuralgias. ²

AGARICUS (Amanita muscaria)
The fungus Amanita muscaria, Persoon; (Agaricus muscarius, Linné.) (Nat. Ord. Fungi.) An extremely poisonous fungus found in the pine forests of... / ...these even the muscarine sulphate or nitrate have been mostly employed, are in colliquative night-sweating from debilitating diseases, and profuse sweating in the daytime; and to restrain the excess o... / ...by Eclectic practitioners. Muscarine is used in atropine and belladonna poisoning, sometimes being employed in place of eserine (physostigmine). ²

APOCYNUM CANNABINUM
The root of Apocynum cannabinum, Linné (Nat. Ord. Apocynaceae) gathered in autumn after the leaves and fruit have matured. Grows throughout the... / ...an of full doses of apocynum are nausea, and sometimes vomiting and purging, succeeded by copious sweating. The pulse is then depressed, and in some a disposition to drowsiness is observed until relie... / ...may be looked for. Under these circumstances we have removed enormous dropsical swellings with it, giving quick relief from dyspnea and²

ARNICA MONTANA
The dried flower-heads of Arnica montana, Linné (Nat. Ord. Compositae). A perennial of Siberia and the cooler parts of Europe; also found in... / ...iary to other treatment. In the hectic fever of phthisis, with exhausting diarrhoea and excessive sweating, it often proves the needed stimulant and antihydrotic. Arnica is a stimulant of great power ...²

BELLADONNA (Atropa belladonna)^ATROP
The (1) dried root and the (2) dried leaves and tops of Atropa Belladonna, Linné (Nat. Ord. Solanaceae). Europe and Central Asia; also... / ...ls local bromidrosis. A weak lotion is effectual in general hyperhydrosis and in the colliquative sweating of phthisis and other debilitating diseases. The ointment and liniment may serve a similar pu...²

BOLETUS
The fungus Polyporus officinalis, Fries (Boletus laricis, jacquin). (Nat. Ord.... / ...drop to 5 drops of the specific medicine. For the last named use that of controlling colliquative sweating, agaric acid or agaricin, as it is more commonly called, is one of the most effectual of anti......t effectual of antihydrotics. In 113 grain doses it controls the thirst, cough, and the excessive sweating of consumptives.²

CALUMBA (Jateorhiza palmata)^JAPA2
The root of Jateorhiza palmata (Lamarck), Miers (Nat. Ord. Menispermaceae). A climbing perennial, the Kalumb of the Southeast coast of Africa.... / ...ch there is lack of desire for food and poor digestion, with pain or without pain, immediately upon eating. After the active stage of cholera morbus, cholera infantum, acute diarrhoea, and dysentery i... / ...local action, and indirectly, by favoring better digestion, the quality of the blood is improved, hence its value in anemia during convalescence.²

COLOCYNTHIS
...ved by colocynth. In atonic dyspepsia, with bitter taste, bitter yellow eructations, bloating after eating, with sharp, griping or cutting pain in the umbilical region minute doses give excellent resu......l in cholera infantum; in chronic diarrhoea with slimy stools and tympanites; in diarrhoea from overeating or improper food; and in dysentery with great tormina, tenesmus and cutting pain, with ineffe...²

CUBEBA
The unripe, full-grown fruits of Piper Cubeba, Linné, fil. (Nat. Ord. Piperaceae.) Java, Borneo, Sumatra, Prince of Wales Island, and other isles... / ...atarrhs, with profuse expectoration, and for nasal catarrh. Smoking cubebs is a popular method of treating nasal catarrh and hay fever. Care must be had not to blister the roof of the mouth, an untowa...²

DUBOISINA
The alkaloid obtained from the leaves of Duboisia myoporoides, Robert Brown (Nat. Ord. Myoporaceae), the Corkwood elm or Ngmoo of Australia and... / ...scarine and has been successfully employed in poisoning by mushrooms. It also checks colliquative sweating. It is reported prompter in action than atropine, and is said to be a better calmative and hy... / ...especially vomiting without previous nausea, and undoubtedly decreases the secretion of urine, hence it should be used with care and judgment.²

DULCAMARA. (Solanum dulcamara)^SODU
The young branches of Solanum Dulcamara, Linné (Nat. Ord. Solanaceae). A vine common in Europe and the United States. Dose, 1 to 30... / ... the kidneys are especially apt to result from immoderate doses. Children are sometimes poisoned by eating the berries of the plant. Scudder suggested dulcamara in small doses in cases of chronic d... / ...remedy in chronic skin diseases of a pustular, vesicular or scaly type, particularly the latter. It may also be tried in pudendal itching.²

EUPATORIUM PERFOLIATUM
The flowering tops and leaves of Eupatorium perfoliatum, Linné (Nat. Ord. Compositae). Swamps and low meadows throughout the United States. Dose,... / ...e bones, praecordial oppression, and great thirst. If, however, the fever lasts all day, slight sweating may occur at night. An added indication in ague is vomiting, especially of much bile. Formerl... / ...tonic and stomachic, when given in small doses it improves the appetite and digestion and thus favors a more rapid and perfect convalescence.²

GRANATUM
The dried bark of the stems and roots of Punica Granatum, Linné (Nat. Ord. Punicaceae). India, southwestern Asia, and the Mediterranean... / ...very effective destroyer. It is sold ready for administration as a single dose. Locke's method of treating tapeworm is popular with Eclectic physicians. The decoction he advised is prepared as follows... / ...Epsom salt, fluidextract of jalap, or castor oil may be used as the cathartic. If the tannate is employed it may be administered in capsule.²

IRIS^IRIS
The rhizome and roots of Iris versicolor, Linné (Nat. Ord. Iridaceae). Common in wet places in the United States. Dose, 5 to 20 grains. Common... / ...ces, with jaundice; nausea and vomiting of sour liquids, or regurgitation of food, especially after eating fats or rich pastry, or ice cream; watery, burning feces; rough, greasy skin, with disorders ...²

Physician's Materia Medica on Eating

IODOSYL
An organic chemical compound containing a little more than 655 of Iodine; empirical formula, C7H4O3I2. An amorphous powder, non toxic and free from irritant action, yet having antiseptic properties that make it invaluable in surgery. It may be used wherever iodo form is now employed with effects at least equally satisfactory. The results obtained with it in treating ulcerations of the cornea are par ticularly gratifying. It may be given internally as a gastric anti septic, in doses of 0.03 to 0.³

NEUTRALIZING CORDIAL (Compound Syrup of Rhubarb and Potassa. N. F.)
Stomachic, laxative, antacid. A favorite remedy with many for certain dyspeptlc conditions, in which constipation and acidity of the stomach are prominent symptoms. Each fluidrachm repre sents; Rhubarb, 2 1/4 grs.; Cinnamon 1 1/8 grs.; Golden-seal, 1 1/8 grs.; Potassium Bicarb., 2 1/4 grs-; Oil Peppermint, 3-50 M Dose, 4 to 8 c. c. (1 to 2 fluidrachms) when distress is felt after eating. It is best taken as much as two hours after a meal.³

OX GALL
The bile of BOS TAURUS, Lin. Antiseptic, laxative, detergent, tonic. Prescribed in chronic constipation and in cases where the natural biliary secretion is deficient; also occasionally as a vermifu ge. Best given two hours after eating, in pill, capsule or tablet form. Dose of the inspissated or purified Ox Gall, 0.3 to 0.6 Grm. (5 to 10 grs.).³

POTASSIUM BICHROMATE (Dichromate)
Alterative, antiseptic, moderately caustic. Prescribed in pro gressive spinal paralysis, gastric ulcer, some forms of dyspepsia and in aphonia; also applied locally in solution to warts, syphilitic vege tations, and as a remedy for fetid perspiration of the feet. Dose, 0.003 to 0.03 Grm. (1-20 to 1/2 gr.); applied in 5% solution for sweating feet; in 10% solution as a caustic.³

WITCH HAZEL (Hamamells)
The leaves, also the bark of HAMAMELIS VIRGINIANA, Lin. Astringent, hemostatic, emollient, vulnerary. The distilled extract is the preparation most used; being indeed a household remedy for sprains, bruises, swellings and injuries of all kinds. It is equally serviceable in the hands of physicians in treating hemorrhoids. passive hemorrhages, in short in all conditions due to relaxation of venous structures.³

Physician's Therapeutics Memoranda on Eating

NEPHRITIS, ACUTE
Prescribe at first aconite, calomel and sodium bicarbonate fol lowed by a saline cathartic; warm mucilaginous drinks, potassium citrate and Ze-an; Glyceroplasma over loins. If uremia is threaten ed, elaterium, Tonic Pilocarpine Compound, hot air baths to cause sweating. In later stages digitalis and squill, caffeine, compound spirit juniper, even cantharides in small doses.³

References

1) Bergner, Pal., Griswold, Alexandra F., Hufford, David J., et al. . Morton Grove, Il: Publications International, 2017.
2) Felter, Harvey Wickes, 1922, The Eclectic Materia Medica, Pharmacology and Therapeutics, Cincinnati, Ohio.
3) Nelson, Baker & Co., 1904, Physician's Handy Book of Materia Medica and Therapeustics, Detroit, Michigan.

Ledgend of Medicine

MODERN MEDICINES

HOME REMEDIES

RANDOM DRUGS

RANDOM AILMENTS

Eating

Eating FDA Approved Drugs

Home Remedies for Eating

Felter's Materia Medica on Eating

Physician's Materia Medica on Eating

Physician's Therapeutics Memoranda on Eating

References